Dr Reddys Laboratories Ltd (DRREDDY) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Dr Reddys Laboratories Ltd on NSE and BSE, with an AI summary of each filing.
Allotment of Employee Stock options
Others (Uncategorized) · 04 Nov 2026, 5:33 pm
Dr. Reddy’s Laboratories Allots Equity Shares Under ADR ESOP Scheme Dr. Reddy’s Laboratories Limited allotted 5,91,270 fully paid-up equity shares of face value Re. 1 each on 4th Nov'26 under its Employees ADR Stock Options Scheme, 2007. The allotments comprise 28,150 shares at Re. 1.00, 2,95,435 shares at Rs. 781.20, 4,225 shares at Rs. 1,060.20, and 2,63,460 shares at Rs. 981.40 per share. Post-allotment, the company's total issued share capital stands at Rs. 83,52,72,555 across 83,52,72,555 shares, while total paid-up capital is Rs. 83,52,71,555. The newly issued shares rank pari passu with existing equity shares.
Clarification - Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015
Others (Uncategorized) · 04 Nov 2026, 5:15 pm
Dr. Reddy’s Clarifies US FDA Tentative Approval for Generic HIV Drug Lenacapavir Dr. Reddy’s Laboratories confirmed media reports regarding US FDA tentative approval for its twice-yearly injectable lenacapavir, aimed at expanding generic HIV prevention access across 120 countries outside the US. Responding to a BSE clarification request dated 3rd Nov'26, the company stated the news relates to its 2nd Nov'26 press release. Dr. Reddy’s highlighted that the development does not constitute a material event or require disclosure under Regulation 30 of SEBI Listing Regulations, maintaining adherence to all mandatory disclosure compliance requirements.
The Exchange has sought Clarification from Dr Reddys Laboratories Ltd with reference to the media report appearing on https://www.firstpost.com dated November 03, 2026 (Link : https://www.firstpost.com/business/indias-dr-reddys-gets-us-nod-for-40-generic-hiv-prevention-shot-for-120-poorer-countries-14057224.html) ....
Others (Uncategorized) · 03 Nov 2026, 11:03 pm
Transcript of Earnings call
Press Release · 30 Oct 2026, 4:23 am
Dr. Reddy’s Laboratories Releases Q2 FY27 Earnings Call Transcript Dr. Reddy’s Laboratories has submitted the transcript of its earnings call held on 23rd Oct'26 for the quarter and half-year ended 30th Sep'26 (Q2 FY27). The disclosure was made pursuant to Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, and the complete transcript is accessible on the company's website.
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015
Others (Uncategorized) · 28 Oct 2026, 11:59 pm
USFDA Closes Inspection at Dr. Reddy's Srikakulam Facility with VAI Classification Dr. Reddy’s Laboratories announced that the USFDA has classified the inspection outcome for its FTO-SEZ Process Unit-02 located in Srikakulam, Andhra Pradesh, as Voluntary Action Indicated (VAI). The Pre-Approval Inspection (PAI) and Good Manufacturing Practices (GMP) audit, originally intimated on 29th Jul'26, is now officially closed under 21 CFR 20.64(d)(3). The VAI status removes regulatory overhang for the facility, clearing a key compliance hurdle for pending and future US product approvals from the site.
Audio Recording of the Earnings call conducted on October 23, 2026
Audio / Video · 24 Oct 2026, 4:42 pm
Dr. Reddy's Laboratories Discloses Audio and Video Links for Q2 Earnings Call Dr. Reddy's Laboratories Limited made available the audio and video recordings of its earnings call conducted on 23rd Oct'26, pursuant to SEBI Listing Regulations. The call pertained to the company's unaudited financial results for the quarter and half-year ended 30th Sep'26. Broadcast links were filed across major listing venues, including the NSE, BSE, NYSE, and NSE IFSC.
Limited Review report of the Statutory Auditors on the Unaudited Financial results for the quarter and half year ended September 30, 2026 with UDIN
Others (Uncategorized) · 24 Oct 2026, 4:01 am
Dr. Reddy’s Submits Auditor Review Reports for Q2 FY27 Results Dr. Reddy’s Laboratories has submitted the Limited Review Reports issued by statutory auditor Deloitte Haskins & Sells LLP for its unaudited standalone and consolidated financial results for the quarter and half-year ended 30th Sep'26. The auditor issued an unmodified review conclusion under Regulation 33 of SEBI Listing Regulations, confirming compliance with Ind AS 34 and finding no material misstatements. Key consolidated entities include Aurigene Discovery Technologies, Betapharm Arzneimittel, Dr. Reddy’s Inc., and its newly incorporated Vietnam subsidiary effective 9th May'25.
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015
Change in Management · 24 Oct 2026, 12:12 am
Dr. Reddy’s Appoints Akhil Ravi as Head API and Services Dr. Reddy’s Laboratories approved the appointment of Akhil Ravi as Head API and Services, designated as Senior Management Personnel and inducted into the Management Council, effective 13th Nov'26. Ravi, who joined the company in 2018 and has nearly 19 years of industry experience, will continue leading operations at wholly owned subsidiary Aurigene Pharmaceutical Services Ltd. as CEO. He is classified as a related party, being the son-in-law of Co-Chairman and Managing Director G V Prasad.
Dr. Reddy's Laboratories Limited has informed the Exchange regarding Outcome of Board Meeting held on October 23, 2026.
Press Release · 24 Oct 2026, 12:11 am
Outcome of Board meeting held on October 23, 2026
Outcome · 24 Oct 2026, 12:09 am
Dr. Reddy’s Reports Q2FY27 Results and Senior Management Appointment Dr. Reddy’s Laboratories reported consolidated Q2FY27 revenues of ₹86,708 Mn, down 1.5% YoY but up 7.4% QoQ, impacted primarily by lower lenalidomide sales in North America (down 23% YoY). EBITDA stood at ₹17,828 Mn with a 20.6% margin, while PAT attributable to equity holders fell 36% YoY to ₹9,250 Mn. Net cash surplus reached ₹25.0 Bn as of 30th Sep'26. Additionally, the board approved the appointment of Mr. Akhil Ravi as Head API and Services and Senior Management Personnel, effective 13th Nov'26.
Copy of Investor Presentation
Investor Presentation · 23 Oct 2026, 11:07 pm
Dr. Reddy’s Reports Q2 FY27 Financial Results Dr. Reddy’s posted Q2 FY27 revenue of ₹8,671 Cr, down 1.5% YoY but up 7% QoQ, impacted by lower lenalidomide sales despite double-digit base business growth. EBITDA fell 24% YoY to ₹1,783 Cr (20.6% margin), while PAT declined 36% YoY to ₹925 Cr. Segmentally, Global Generics stood at ₹7,793 Cr, driven by Emerging Markets (+24% YoY) and India (+17% YoY), offsetting North America (-23% YoY). Aurigene CDMO crossed $100+ million annual revenue. Net cash surplus closed at ₹2,502 Cr as of 30th Sep'26.
Unaudited Financial results for quarter and half year ended September 30, 2026
Financial Result · 23 Oct 2026, 11:00 pm
Dr. Reddy's Laboratories Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
Outcome · 23 Oct 2026, 10:59 pm
Dr Reddys Laboratories Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Million) ■ Revenue: 86,978 (-1.5% YoY | +7.4% QoQ) ■ EBITDA: 17,306 (-13.9% YoY | +101.3% QoQ) ■ EBITDA Margin (%): 19.9 (-287 bps YoY | +928 bps QoQ) ■ PAT: 9,248 (-31.3% YoY | +108.1% QoQ) ■ EPS (INR): 11.1 (-31.4% YoY | +108.1% QoQ) Dr Reddys Laboratories Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Million) Segmental Performance Global Generics ■ Revenue: 77,965 (-0.3% YoY | +8.2% QoQ) ■ EBIT: 43,833 (-5.6% YoY | +18.1% QoQ) ■ EBIT Margin (%): 56.2 (-313 bps YoY | +472 bps QoQ) Pharmaceutical Services and Active Ingredients ■ Revenue: 10,636 (-11.9% YoY | -0.9% QoQ) ■ EBIT: 984 (-42.3% YoY | +154.9% QoQ) ■ EBIT Margin (%): 9.3 (-487 bps YoY | +565 bps QoQ) Others ■ Revenue: 482 (+368.0% YoY | +149.7% QoQ) ■ EBIT: 391 (+7720.0% YoY | +986.1% QoQ) ■ EBIT Margin (%): 81.1 (+7627 bps YoY | +6247 bps QoQ)
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015
Press Release · 21 Oct 2026, 3:09 pm
Dr. Reddy’s Secures DCGI Approval for Zytorvi in Advanced Esophageal Cancer Dr. Reddy’s Laboratories received DCGI approval for Zytorvi (toripalimab), in combination with cisplatin and paclitaxel, as a first-line treatment for advanced esophageal squamous cell carcinoma (ESCC) regardless of PD-L1 biomarker status. This marks Zytorvi's second approved indication in India, following nasopharyngeal carcinoma. Phase 3 JUPITER-06 trial data showed the regimen reduced disease or death risk by 42%, extending median overall survival to 17.7 months versus 12.9 months for chemotherapy alone. Dr. Reddy’s holds exclusive licensing rights for toripalimab across 21 countries.
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015
Others (Uncategorized) · 15 Oct 2026, 1:50 am
USFDA Issues Form 483 with Three Observations for Dr. Reddy’s Visakhapatnam Facility The USFDA completed a Pre-Approval Inspection at Dr. Reddy’s Laboratories’ FTO-9 manufacturing facility in Visakhapatnam, Andhra Pradesh, conducted between 8th Oct'26 and 9th Oct'26. Following the audit, the regulator issued a Form 483 containing three observations. Dr. Reddy’s confirmed that it will address all observations within the stipulated timeline.
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015
Others (Uncategorized) · 08 Oct 2026, 9:25 pm
USFDA Issues Form 483 with Two Observations for Dr. Reddy's FTO-11 Facility The USFDA concluded a Pre-Approval Inspection (PAI) at Dr. Reddy’s Laboratories' FTO-11 manufacturing facility in Pydibhimavaram, Andhra Pradesh, conducted between 5th Oct'26 and 7th Oct'26. Following the audit, the regulator issued a Form 483 containing two observations. The company stated it will address the cited observations within the stipulated timeline.
Intimation of Earnings call
Press Release · 07 Oct 2026, 8:08 pm
Dr. Reddy's Schedules Q2FY27 Results and Earnings Call for 23rd Oct'26 Dr. Reddy's Laboratories Ltd. will announce its financial results for the quarter and half-year ended 30th Sep'26 on 23rd Oct'26, following its Board Meeting. The management will subsequently host an earnings conference call on the same day at 19:30 IST (10:00 ET) to discuss the company's financial performance. Financial results, the press meet presentation, and the earnings call audio and transcripts will be made available on stock exchanges and the company's official website.
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015
Others (Uncategorized) · 03 Oct 2026, 10:40 pm
Dr. Reddy's US Subsidiary Incurs Minor Penalty From US IRS Dr. Reddy’s Laboratories announced that its step-down wholly owned subsidiary, Dr. Reddy’s Laboratories, Inc., received a transcript dated 25th Sep'26 from the US Internal Revenue Service on 2nd Oct'26 levying a penalty of $32,350.20. The penalty was imposed due to a misclassification of the fiscal year reference during tax payment. The company confirmed that the levy has no material impact on its financial position, operations, or broader business activities.
Dr. Reddy's Laboratories Limited has informed the Exchange about Board Meeting to be held on 23-Oct-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Quarterly ended September 2026 .
Intimation · 23 Oct 2026, 5:30 am
Dr Reddys Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/10/2026 ,inter alia, to consider and approve Unaudited Standalone ....
Intimation · 23 Oct 2026, 5:30 am
Dr. Reddy's Schedules Board Meeting on 23rd Oct'26 to Consider Q2 Results Dr. Reddy’s Laboratories Limited announced that its Board of Directors will meet on 23rd Oct'26 to consider and approve the unaudited standalone and consolidated financial results for the quarter ending 30th Sep'26. In accordance with SEBI insider trading regulations, the trading window for dealing in the company's securities will remain closed from 24th Sep'26 through 25th Oct'26 (both days inclusive).
Intimation of analyst meet
Intimation · 21 Sept 2026, 10:21 pm
Dr. Reddy’s Laboratories Scheduled for Institutional Investor Meeting Dr. Reddy’s Laboratories announced under SEBI Regulation 30 that company management will participate in an investor conference organized by Nomura. The in-person group meeting is scheduled for 25th Sep'26 from 11:00 to 14:00 IST in Hyderabad. The schedule remains subject to changes arising from any exigencies.
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015
Press Release · 18 Sept 2026, 2:30 pm
Dr. Reddy’s Partners with Takeda for Dengue Vaccine Distribution in India Dr. Reddy's Laboratories entered into an exclusive agreement on 18th Sep'26 with Takeda Biopharmaceuticals India to distribute and market Qdenga®, India’s first CDSCO-approved dengue vaccine, across the domestic private market for individuals aged 4–60 years. Takeda will handle manufacturing, importation, and public market rights, retaining legal ownership. The agreement entails no upfront consideration or milestone payments. The vaccine is anticipated to launch in H1'27, strengthening Dr. Reddy's domestic vaccines portfolio amid rising dengue prevalence.
Clarification- Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015
Others (Uncategorized) · 18 Sept 2026, 2:11 pm
Dr. Reddy's Confirms Voluntary Licensing Agreement with Gilead for HIV Drug Dr. Reddy’s Laboratories confirmed on 18th Sep'26 that it entered into a voluntary licensing agreement with Gilead Sciences for investigational once-yearly lenacapavir used in HIV prevention, validating media reports from 17th Sep'26. Clarifying a query from BSE regarding trading movement, the company stated the agreement does not constitute a material event requiring separate disclosure under Regulation 30 of SEBI Listing Regulations, confirming there is no unannounced material information or ongoing regulatory proceedings.
The Exchange has sought clarification from Dr Reddys Laboratories Ltd on September 17, 2026, with reference to news appeared in https://pharma.economictimes.indiatimes.com/ dated September ....
Others (Uncategorized) · 17 Sept 2026, 9:28 pm
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015
Others (Uncategorized) · 12 Sept 2026, 3:37 am
USFDA Completes Records Assessment at Dr. Reddy’s Mexico Facility with Two Observations The USFDA concluded a records assessment under Section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act for Dr. Reddy’s Laboratories' API manufacturing facility in Jiutepec, Morelos, Mexico (Industrias Químicas Falcón de México). Conducted between 17th Jul'26 and 8th Sep'26, the inspection resulted in the issuance of a Form FDA 2953 with two observations. The company stated it will respond to the observations within the stipulated timeline.